1 Chikungunya Seroprevalence among Patients Presenting with Febrile illnesses in selected health

- 2 facilities in Mt. Elgon region, Kenya.
- 3 Sheila Kageha¹, Joyce M. Ngoi², Toru Kubo³, Kouichi Morita³ and Matilu Mwau¹
- 4 Corresponding Author: Sheila Kageha
- 5 Mail: skageha@kemri.go.ke
- 6 P.O. Box 54628 Nairobi -00200, Kenya
- 7 Tel. +254 722-587808

8 Authors and Institutional Affiliations

9 ¹Kenya Medical Research Institute, Kenya

²West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and
 Applied Sciences, University of Ghana, Accra, Ghana.

³Department of Virology, Institute of Tropical Medicine, Nagasaki University, Japan.

13

14 Abstract

15 Background

16 Chikungunya is an emerging epidemic-prone vector-borne disease of considerable significance globally. 17 Infection with chikungunya virus induces an acute illness characterized by fever and painful arthralgia, 18 which can evolve to chronic arthritis and rheumatism especially in elderly patients. Whereas febrile 19 illness and arthralgia are common clinical presentations amongst residents of Mt. Elgon, the role of 20 chikungunya virus as a causative agent is undocumented. This study was carried out to determine the 21 prevalence of IgA, IgM and IgG antibodies against Chikungunya Virus (CHIKV) antigens in patients 22 presenting with acute febrile illnesses in Mt. Elgon region, Kenya.

Methods: This was a cross-sectional seroprevalence study on febrile patients visiting Endebes, Andersen
 and Kitale County Referal Hospitals. Sociodemographic data was collected whenever possible. Serum
 samples were collected and screened using Indirect ELISA for 1gG+IgM+IgA antibodies. Sera that tested

positive by ELISA were subjected to standard plaque reduction neutralization assays (PRNT) performed
 on monolayer cultures of Vero E6 cells for confirmation.

28 Results: By ELISA, a total of 317/1359 (23.33%) sera were positive for CHIKV antibodies. Of the 317

- 29 positive sera, 305 (96.21%) were of sufficient quantity and were subjected to PRNT. Ultimately, 127
- 30 (9.3%) samples tested positive for CHIKV neutralising antibodies by PRNT.

Conclusion: These findings suggest active circulation of CHIKV in Mt. Elgon, even though it has previously been considered a non-endemic region for the virus. There is need to closely monitor and continuously put in place surveillance strategies to prevent probable potential outbreaks in the future.

34 Key words: Chikungunya virus (CHIKV), Seroprevalence survey, Kenya, Mt. Elgon

35 Introduction

36 Chikungunya virus (CHIKV), an alphavirus of the Togaviridae family [1-4], was originally isolated in 37 1952-53 from the serum of a febrile patient during an outbreak that occurred in the Makonde Plateau in 38 the southern region of Tanzania [5]. It has since spread, infecting millions of people globally. CHIKV 39 infection is commonly characterised by acute fever, headaches and painful arthralgia, which can evolve to 40 chronic arthritis and rheumatism especially in elderly patients [5-7]. These symptoms are often clinically indistinguishable from those caused by other arboviruses such as dengue, Onyong' nyong' (ONNV) and 41 West Nile viruses (WNV). Similarities in clinical symptoms often lead to missed opportunities to detect, 42 43 and consequent underreporting of CHIKV infection in areas endemic to arbovirus infections [8, 9]. 44 CHIKV has become a global public health threat with reported cases of neurologic involvement, fulminant hepatitis, and neonatal encephalopathy[10, 11]. Neurological forms of the disease and severe 45 cases have also been reported in the Réunion island outbreak of 2005-2006 and in Italy [12-14]. 46

47 Currently there are no licensed specific antiviral drugs or vaccines to prevent CHIKV infection. 48 Treatment is mainly supportive and entails the use of analgesic drugs in combination with non-steroidal 49 anti-inflammatory drugs for symptomatic relief [15-17]. Patients infected with CHIKV develop robust 50 innate and adaptive immune responses that help in viral clearance and protection. Neutralising anti-51 CHIKV IgG persists for at least 21 months [18-20].

52 CHIKV circulates in a sylvatic cycle between non-human primates/mammalian reservoir hosts and *Aedes* 53 *spp.* of mosquitoes [21]. *Aedes aegypti* is responsible for CHIKV endemicity in the tropical and sub-54 tropical regions while *Aedes albopictus* has been associated with spread in temperate regions including 55 southern Europe, the Caribbean and southern and eastern regions of the USA. The virus is transmitted to

human hosts via infectious bites from *Aedes spp.* of mosquitoes [22, 23]. There has been increased frequency of CHIKV outbreaks in previously non-endemic regions, which has been attributed to the expansion of mosquito vector species and genetic adaptation of the virus that enhances its transmissibility [24-26].

60 CHIKV originally endemic in Africa is known for its wide geographic distribution. In Africa, there have 61 been reports of human infection from Angola, Democratic Republic of Congo, Mozambique, Gabon, 62 Nigeria, Southern Africa, Tanzania, Uganda, and Burundi [27-31]. Chikungunya has since spread to Asia 63 including India and in the island countries of the Indian Ocean, Europe and America. In America, the 64 virus has been identified in 45 states, and more than 2.9 million suspected and confirmed cases and 296 65 deaths have been reported [32]. In Asia, CHIKV was first isolated in Bangkok, Thailand in 1958 [29, 33].

The disease was formerly thought to be self-limiting until the Reunion Island outbreaks in 2005-2006 that
witnessed several fatalities. Brazil has also experienced fatalities resulting from Chikungunya outbreak
[34].

69 In Kenya, the first outbreaks of CHIKV infection were recorded in Lamu and Mombasa in 2004[35, 36]. 70 Indeed, genetic analysis of the virus responsible for the Indian Ocean epidemic showed that it originated 71 in the Kenvan Coast. CHIKV vectors are commonly found in diverse habitats, and there is reason to 72 believe that CHIKV outbreaks have occurred before. Mt. Elgon region in Trans Nzoia County has 73 substantial populations of reservoir hosts, high vector infestation and favourable climatic conditions for 74 transmission of arboviruses. Furthermore, encroachment of human populations into forested areas for 75 agricultural land has led to increased exposure to sylvatic mosquitoes that vector these viruses. This study aimed to determine the seroprevalence of CHIKV infection in febrile patient population presenting in 76 77 selected health facilities in the region.

78

79 Materials and Methods

80 Study sites and specimen collection

This was a cross-sectional study conducted to determine the seroprevalence of CHIKV in febrile patients visiting health facilities in Mt. Elgon region. Mt. Elgon ecosystem comprises a forest reserve and a national park. The surrounding areas are heavily forested. The slopes of the mountain nearby have several caves, infested with bats and other rodents. The livelihoods of the population is mainly linked to

agricultural production. This has seen encroachment of the forest for cultivation and exploitation of forest
 products such as fuelwood, medicinal herbs, posts and poles, grazing and hunting for wild game.

The study was carried out in three health facilities located in the region: Andersen Medical centre (AMC), Endebes District hospital (END) and Kitale County Referral hospital (KCRH within the County. These facilities serve a large part of Trans Nzoia County. With consent, venous blood samples were collected from patients \geq 5 years of age presenting with acute febrile illnesses. Structured questionnaires were used to collect socio-demographic and clinical information from a subset of study participants. Ethical approval for the study protocol was sought from Kenya Medical Research Institute Ethical Review Committee under SSC No.1698. All samples were anonymized at collection by assigning unique codes.

Storage was at -20° C at the facilities. Samples were transported in dry ice for processing at KEMRI,
where sera were separated, aliquoted into vials and stored at -80°C.

96 Laboratory Assays

Sera were tested for 1gG+IgM+IgA antibodies against CHIKV and neutralizing antibodies against 97 98 CHIKV for those that tested positive by ELISA. All sera were first tested for antibodies against CHIKV antigens by enzyme-linked immunosorbent assay (ELISA). An in-house indirect ELISA was performed 99 100 according to the methods described in the Igarashi Technical Manual (2000) with some modifications. 101 Purified CHIK viruses from infected culture fluid of C6/36 cells were used as antigens. Polyethylene glycol and NaCl was used to concentrate the virus antigens, which were then purified using sucrose-102 gradient ultracentrifugation at 50000g, for 14h at 4 °C (Bundo and Igarashi, 1983) [50]. The viral antigens 103 104 were diluted at 250ng/100 µL with phosphate buffered saline (PBS). High- protein-binding 96-well microplates (Maxisorp; Nulgenunc international, Roskilde, Denmark) were coated with 250ng/100 105 μ L/well viral antigen, wrapped and incubated overnight at 4 $^{\circ}$ C. Blocking was done by adding 100 μ L of 106 PBS, 3% FCS (PBS-F) to all the wells and then incubated for 30 min at RT. The test sera were diluted at 107 1/1000 with PBS-F and added in duplicates to the pre-coated plates and incubation done at $37^{\circ}C$ for 1 hr. 108 109 Control sera (both positive and negative controls) were run on each plate. After incubation, the plate was 110 washed three times with PBS, 0.05% Tween-20. 100 µL/well of 1:5000 diluted horseradish-conjugated goat anti-human IgG+M+A (American Qualex, A139PN) [37] was added to the wells and incubated at 37 111 [°]C for 1h followed by washing three times. A substrate solution consisting of 5mg O-Phenylenediamine 112 dihydrochloride (OPD) (Sigma Chemical, St. Louis, MO) was added and incubated for 15 min at RT in 113 114 the dark. 100 μ L/well of 5N Sulfuric acid was then added to stop further reaction. Absorbance (OD) of

each well was determined using spectrophotometer at 492nm. OD specific for CHKV was calculated as
follows [(Mean OD of virus coated wells) – (Mean OD of PBS-F coated wells)]. A serum sample was
deemed positive if the mean OD difference was >1.

118 Virus neutralization assay

119 CHIKV antigens obtained from bulk virus cultures and purified by sucrose density gradient ultracentrifugation were used in this assay. Titres of virus stocks were determined by plaque assays in 120 Vero cells expressed as plaque-forming units (PFU) per mL. All patient sera positive by IgG+IgM+IgA 121 ELISA were subsequently subjected to PRNT (protocol adapted from Igarashi Technical Manual, 2000). 122 123 This assay was used to determine the presence of CHIKV specific neutralizing antibodies in the test sera. The PRNTs were performed using Vero E6 cells. CHIKV prototype strain (S 27) was used for this 124 experiment. PRNT plates were prepared by seeding Vero cells at a concentration of 1 x 10⁵ cells/ml into 125 126 6-well plates at a volume of 3 ml/well. The cells were cultured in Growth Medium (EMEM (Gibco), 10% FCS (Gibco), L-glutamine P/S (Gibco), 0.2mM NEAA (Gibco), NaHCO3 supplemented for 1 day at 127 128 37°C, 5% CO₂ until the cells had attained 80% confluence. Test serum was diluted with Maintenance Medium (MM) (EMEM, 2% FCS, L-glutamine, P/S, NEAA, NaHCO3 supplemented) into 1:10 dilutions. 129 130 At the same time, standard virus dilution of 1000 PFU/ml with MM was prepared. An equal volume of 131 serum dilution (100µL) and standard virus dilution (100µL) was mixed. For positive control wells, equal volumes of MM and standard virus dilution were mixed. The virus-serum mixture was then incubated for 132 1 hour at 37°C. After 1h incubation of mixture, 2.5 ml of culture medium from each well of 6-well plates 133 was aspirated and 100 μ l/well of serum/virus mixture added to Vero cells in duplicate wells. The plates 134 were then incubated for 1.5 - 2 hours in the 37°C, 5% CO₂ incubator. A total of 3ml of overlay medium 135 136 (EMEM, 2% FCS, 1.4% Methylcellulose, P/S supplemented) was added into each well, and incubated at 37°C, 5% CO₂ for 2-3 days with daily observation. Harvesting involved discarding of overlay medium 137 and fixing plates by adding 1 ml of 10% formalin in PBS over the cell and incubation for 1 hour at room 138 139 temperature (rt) in the safety cabinet under UV light. After incubation, the plates were then washed gently 140 with tap water at least twice, absorbed on paper towel and staining solution (0.5 ml of 1% Crystal Violet 141 solution in water) added. The stain was discarded after 5-10 minutes at room temperature and plates washed gently with tap water. The plates were air-dried at room temperature and plaques counted for each 142 set of duplicate wells. The percentage reduction was calculated by comparing with the positive control 143 144 virus well (100% plaque formation). Sera were initially tested at a dilution of 1:20 and those that reduced the number of plaques by \geq 75% (PRNT₇₀) were titrated. More than 90% plaque reduction (PRNT₉₀) was 145

regarded as positive and titers were expressed as the reciprocal of serum dilutions yielding $\geq 90\%$ reduction in the number of plaques.

148 Data analysis

149 Data analyses were performed using STATA Version 14 software (Stata Corp LP, College Station, Texas,

- 150 United States). Chi-square test was performed for potential association. Two-sided p values were
- 151 reported, and statistical significance was taken as p < 0.05.

152 **Results**

A total of 1,398 samples were collected from febrile patients in the selected health facilities and screened
 for CHIKV antibodies. Thirty-nine (39, 2.79%) patient sera were excluded from analysis for various
 reasons including insufficient sera volume and compromised sample integrity.

The main inclusion criterion for this study was fever. The minimum temperature was 38°C while the maximum was 40.5°C with a mean of 39.1°C. The median duration of fever was nine days. Forty-three patients complained of muscle pains. Other complaints included: jaundice, body pains, abdominal pains, diarrhoea and bleeding.

160 Demographic and clinical data was available for 782/1,359 (57.54%) samples: 507 (37.31%) were 161 collected from females and 275 (20.24%) from males (Table 1). The average age of the participants was 31.6 years (Median 28, range 5-91 years). There was no significant difference in ages between males and 162 females, (median 31.4 and 31.7 respectively, p > 0.6). Data on residence of patients was available for 777 163 samples. Majority of the people resided in formerly Rift Valley Province (83.71%), followed by Western 164 Province (2.1%), Eastern Uganda (11.2%) while the rest (3%) were non-residents. Of the 1,359 samples 165 166 processed successfully, 689 (50.70%) were from KCRH, 463 (34.07%) from AMC and 207 (15.23%) from END. A total of 317 (23.34%) samples tested antibody positive by ELISA. 167

168 The odds of exposure were determined for gender, health facilities, age of participants and presenting 169 symptoms (Table 1). The odds of being seropositive for CHIKV were significantly lower in END and 170 KCRH when compared with AMC, in those with fever when compared to those without, those with eye 171 infection and headache when compared to those without (p<0.05).

Table 1: Poisson Regression Analysis for Chikungunya Virus (CHIKV) Seropositivity
 among febrile patients visiting selected health facilities in Mt. Elgon Region.

	Total pop.	CHIKV	CHIKV +ve (n=317)			
Participant characteristics	n (%)	OR	95% CI	p value		
Gender	·	•		·		
Male	275 (20.24)	Ref.				
Female	507 (37.31)	0.68	0.45 - 1.04	0.08		
Missing data*	577 (42.46)	0.29	0.19 - 0.43	0.00		
Age Group (Years)						
0 - 5.0	12 (0.88)	2.3	0.30 - 1.81	0.43		
5.1- 20	154 (11.33)	1.08	0.65 - 1.77	0.77		
20.1 - 35	376 (27.67)	Ref.				
35.1- 50	128 (9.42)	1.13	0.65 - 1.95	0.67		
50.1 - 100	84 (6.18)	1.14	0.83-3.66	0.14		
Missing data*	605 (44.52)	0.43	0.31-0.59	0.001		
Health Facility						
AMC	463 (34.07)	Ref.				
END	207 (15.23)	0.35	0.22 - 0.56	0.00		
KCRH	689 (50.70)	0.72	0.55 - 0.94	0.01		
Presenting symptoms						
Fever						
No	205 (15.08)	Ref				
Yes	567 (41.72)	0.48	0.32 - 0.72	0.00		
Missing data*	587 (43.19)	1.58	1.10 - 2.28	0.013		
Rash						
No	556 (40.91)	Ref.				
Yes	224 (16.48)	1.07	0.70 - 1.62	0.76		
Missing data*	579 (42.62)	2.72	2.03 - 3.64	0.00		
Eye infection						
No	617 (45.40)	Ref.				
Yes	159 (11.70)	0.53	0.30 - 0.92	0.023		
Missing data*	583 (42.90)	2.35	1.79 -3.09	0.00		
Jaundice						
No	659 (48.49)	Ref				
Yes	115 (8.46)	1.06	0.62 - 1.80	0.84		
Missing data*	585 (43.05)	2.67	2.02 - 3.52	0.00		
Headache						
No	205 (15.08)	Ref.				
Yes	568 (41.80)	0.54	0.36 - 0.82	0.00		
Missing data*	586 (43.12)	1.72	1.19 - 2.50	0.00		

174

*Sociodemographic characteristics and clinical data were not collected for the first 605 study
participants. KCRH, Kitale County Referral Hospital, AMC, Andersen Medical Center; END,
Endebes District Hospital.

178

Of the 317 samples that tested antibody positive by ELISA, 305 (96.21%) were further subjected to PRNT for CHIKV-specific neutralizing antibodies. A total of 123 (40.33%) exhibited neutralizing activities for CHIKV antigens. An additional four (4) samples that were borderline negative by ELISA

182 tested PRNT positive (Table 2).

	CHIKV PRNT		
ELISA Status	Neutralizing	None Neutralizing	Total
	4	1	5
NEG	80.00	20.00	100.00
	123	177	300
POS	41.00	59.00	100.00
	127	178	305
Total	41.64	58.36	100.00

Table	2:	ELISA	versus	PRNT	Results	for	CHIKV
-------	----	-------	--------	------	---------	-----	-------

183

184 Discussion

Our study observed an overall seroprevalence of 23.34% (317) by ELISA. PRNT results were positive for 9.35% (127) of all samples, confirming CHIKV activity in the region. Mt. Elgon region exhibits extraordinary biodiversity due to the presence of forests, rivers, high levels of humidity and vertebrate reservoirs that provides potential *Aedes spp*. breeding habitats. These ecological settings provide opportunities for multiplication and the spread of vector-borne viruses in the region.

Agriculture is the main economic activity in the region. This has seen encroachment on forest reserves for cultivation and exploitation of forest products such as fuelwood, medicinal herbs, timber, grazing and hunting for wild game; increasing exposure to the sylvatic mosquitoes that vector these viruses. Aedes spp. responsible for CHIKV transmission have been reported in Western Kenya in previous studies [38, 39].

195 The high seropositivity in this study compares with findings from past studies in the area, indicating that 196 alphaviruses, though subtle, are actively circulating in the region [40]. Other studies in Cameroon, Benin,

Mozambique and Guinea have shown similar results, which suggest a significant and unrecognizedCHIKV circulation in Africa[41-44].

In this study, we could not ascertain with confidence whether the seropositivity observed was due to present or convalescent CHIKV and/or ONNV infections. Little is known about the lifeline of circulatory CHIKV specific antibodies, beyond what is generally known about the kinetics of IgG and IgM antibodies with other immune correlates. However, herd immunity has been demonstrated in populations with constant contact with vectors, this could explain the observed neutralization [44, 45].

204

205 Of interest, were samples that tested positive by ELISA but failed to neutralize the CHIKV antigens by PRNT 178/305 (58.36%). This suggests possible IgM/IgG cross-reactivity to closely related alphaviruses 206 207 circulating in the region. CHIKV belongs within the Semliki Forest virus (SFV) antigenic serocomplex 208 and therefore exhibits serological cross-reactivity[45, 46]. Co-infections with more than one etiological 209 agent have been shown to complicate diagnosis, severity and management of these viruses in patients [47, 48]. More diverse studies to assess CHKV antibody persistence and the likelihood of cross-protection 210 against CHIKV infection due to previous alphavirus infection could provide better insights. Findings 211 212 from related studies have indicated multiple genotypes that could have effects on serological outcomes 213 and epidemic potential [27, 49].

In Kenya, especially in malaria endemic regions, malaria is frequently diagnosed as the cause of acute undifferentiated febrile illnesses while other causes like arboviruses are often overlooked. This study suggests that CHIKV is an important cause of fever in Mt. Elgon and should be considered as a differential diagnosis in clinical practise.

This study had limitations such as incomplete and insufficient demographics and clinical information thathampered analysis for odds of exposure among the population.

220

221 Conclusion

From this study, we conclude that CHIKV commonly infects residents of Mt. Elgon, and is underrecognized as a cause of morbidity in this population. Therefore, periodic surveillance is necessary to assess the viral burden in the population and devise effective public health interventions to tackle the challenge. Vector control measures are also needed to curb these infections.

226

227 Author Disclosure Statement

228 The authors declare that they have no competing interests.

229 Acknowledgement

- 230 This study was supported by Nagasaki University of Infectious and Tropical Medicine in collaboration
- with the Kenya Medical Research Institute. This study appreciates the Deputy Director, Centre for Virus
- research and the technical staff for support.

233 References

- Higashi N, Matsumoto A, Tabata K, Nagatomo Y: Electron microscope study of development of
 Chikungunya virus in green monkey kidney stable (VERO) cells. *Virology* 1967, 33(1):55-69.
- Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, Strauss JH, Weaver SC: Evolutionary
 relationships and systematics of the alphaviruses. Journal of virology 2001, 75(21):10118 10131.

- Lahariya C, Pradhan SK: Emergence of chikungunya virus in Indian subcontinent after 32 years:
 A review. Journal of vector borne diseases 2006, 43(4):151-160.
- 2435.Robinson MC: An epidemic of virus disease in Southern Province, Tanganyika Territory, in2441952-53. I. Clinical features. Transactions of the Royal Society of Tropical Medicine and Hygiene2451955, 49(1):28-32.
- Miner JJ, Aw-Yeang HX, Fox JM, Taffner S, Malkova ON, Oh ST, Kim AHJ, Diamond MS, Lenschow
 DJ, Yokoyama WM: Chikungunya viral arthritis in the United States: a mimic of seronegative
 rheumatoid arthritis. Arthritis & rheumatology (Hoboken, NJ) 2015, 67(5):1214-1220.
- Weaver SC: Arrival of chikungunya virus in the new world: prospects for spread and impact on
 public health. *PLoS neglected tropical diseases* 2014, 8(6):e2921.
- 251 8. Carey DE: Chikungunya and dengue: a case of mistaken identity? Journal of the history of
 252 medicine and allied sciences 1971, 26(3):243-262.
- Seneviratne SL, Perera J: Fever epidemic moves into Sri Lanka. BMJ (Clinical research ed) 2006,
 333(7580):1220-1221.
- Rampal, Sharda M, Meena H: Neurological complications in Chikungunya fever. The Journal of
 the Association of Physicians of India 2007, 55:765-769.
- 25711.Wielanek AC, Monredon JD, Amrani ME, Roger JC, Serveaux JP: Guillain-Barré syndrome258complicating a Chikungunya virus infection. Neurology 2007, 69(22):2105-2107.
- Tournebize P, Charlin C, Lagrange M: [Neurological manifestations in Chikungunya: about 23 cases collected in Reunion Island]. *Revue neurologique* 2009, 165(1):48-51.
- Lemant J, Boisson V, Winer A, Thibault L, André H, Tixier F, Lemercier M, Antok E, Cresta MP,
 Grivard P *et al*: Serious acute chikungunya virus infection requiring intensive care during the
 Reunion Island outbreak in 2005-2006. *Critical care medicine* 2008, 36(9):2536-2541.
- Elsinga J, Gerstenbluth I, van der Ploeg S, Halabi Y, Lourents NT, Burgerhof JG, van der Veen HT,
 Bailey A, Grobusch MP, Tami A: Long-term Chikungunya Sequelae in Curaçao: Burden,
 Determinants, and a Novel Classification Tool. The Journal of infectious diseases 2017,
 267 216(5):573-581.

Strauss JH, Strauss EG: The alphaviruses: gene expression, replication, and evolution.
 Microbiological reviews 1994, 58(3):491-562.

- 26815.Brighton SW: Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open269pilot study. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1984,27066(6):217-218.
- Staikowsky F, Le Roux K, Schuffenecker I, Laurent P, Grivard P, Develay A, Michault A:
 Retrospective survey of Chikungunya disease in Reunion Island hospital staff. *Epidemiol Infect* 2008, **136**(2):196-206.
- De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R:
 On chikungunya acute infection and chloroquine treatment. *Vector Borne Zoonotic Dis* 2008,
 8(6):837-839.
- Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Rénia L *et al*: Longitudinal analysis of the human antibody response to Chikungunya virus infection:
 implications for serodiagnosis and vaccine development. *Journal of virology* 2012, 86(23):13005-13015.
- Seymour RL, Adams AP, Leal G, Alcorn MD, Weaver SC: A Rodent Model of Chikungunya Virus
 Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation. *PLoS neglected tropical diseases* 2015, 9(6):e0003800.
- 284 20. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle
 285 KM, Fong RH *et al*: Isolation and Characterization of Broad and Ultrapotent Human
 286 Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. *Cell host & microbe* 2015, 18(1):86-95.
- Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M: Chikungunya, an epidemic arbovirosis. *The Lancet Infectious diseases* 2007, 7(5):319-327.
- 22. Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D: Vectors of Chikungunya virus in Senegal:
 current data and transmission cycles. *The American journal of tropical medicine and hygiene* 1999, 60(2):281-286.
- Arias-Goeta C, Mousson L, Rougeon F, Failloux AB: Dissemination and transmission of the E1 294 226V variant of chikungunya virus in Aedes albopictus are controlled at the midgut barrier
 295 level. *PloS one* 2013, 8(2):e57548.
- 296 24. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S: A single mutation in chikungunya virus
 297 affects vector specificity and epidemic potential. *PLoS pathogens* 2007, 3(12):e201.
- 29825.Horwood PF, Buchy P: Chikungunya. Revue scientifique et technique (International Office of299Epizootics) 2015, 34(2):479-489.
- Tsetsarkin KA, Weaver SC: Sequential adaptive mutations enhance efficient vector switching by
 Chikungunya virus and its epidemic emergence. *PLoS pathogens* 2011, 7(12):e1002412.
- 30227.Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A,303Herrero LJ et al: Chikungunya virus: an update on the biology and pathogenesis of this304emerging pathogen. The Lancet Infectious diseases 2017, 17(4):e107-e117.
- Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, Bedno S, Burke H, Dumilla AM,
 Konde J *et al*: Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,
 October 2004. *The American journal of tropical medicine and hygiene* 2008, 78(2):333-337.
- Bhatia R, Narain JP: Re-emerging chikungunya fever: some lessons from Asia. Tropical medicine
 & international health : TM & IH 2009, 14(8):940-946.
- 30. Pastorino B, Muyembe-Tamfum JJ, Bessaud M, Tock F, Tolou H, Durand JP, Peyrefitte CN:
 Epidemic resurgence of Chikungunya virus in democratic Republic of the Congo: identification
 of a new central African strain. Journal of medical virology 2004, 74(2):277-282.
- 31331.D'Ortenzio E, Grandadam M, Balleydier E, Jaffar-Bandjee MC, Michault A, Brottet E, Baville M,314Filleul L: A226V strains of Chikungunya virus, Réunion Island, 2010. Emerging infectious315diseases 2011, 17(2):309-311.

316 32. Centers for Disease Control and Prevention tUSoACvgdAfhwcgcgihLu.

- 317 33. Arankalle VA, Shrivastava S, Cherian S, Gunjikar RS, Walimbe AM, Jadhav SM, Sudeep AB, Mishra
 318 AC: Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to
 319 the 2005-2006 explosive epidemic. *The Journal of general virology* 2007, 88(Pt 7):1967-1976.
- 32034.Brito CAA: Alert: Severe cases and deaths associated with Chikungunya in Brazil. Revista da321Sociedade Brasileira de Medicina Tropical 2017, 50(5):585-589.
- 322 35. Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CHL, Sang R, Sergon K,
 323 Breiman R, Powers AM: Tracking epidemic Chikungunya virus into the Indian Ocean from East
 324 Africa. The Journal of general virology 2008, 89(Pt 11):2754-2760.
- 325 36. Sang RC, Ahmed O, Faye O, Kelly CL, Yahaya AA, Mmadi I, Toilibou A, Sergon K, Brown J, Agata N
 326 *et al*: Entomologic investigations of a chikungunya virus epidemic in the Union of the Comoros,
 327 2005. The American journal of tropical medicine and hygiene 2008, 78(1):77-82.
- 328 37. Peyrefitte CN, Rousset D, Pastorino BA, Pouillot R, Bessaud M, Tock F, Mansaray H, Merle OL,
 329 Pascual AM, Paupy C *et al*: Chikungunya virus, Cameroon, 2006. *Emerg Infect Dis* 2007,
 330 13(5):768-771.
- 331 38. Eastwood G, Sang RC, Guerbois M, Taracha ELN, Weaver SC: Enzootic Circulation of
 332 Chikungunya Virus in East Africa: Serological Evidence in Non-human Kenyan Primates. The
 333 American journal of tropical medicine and hygiene 2017, 97(5):1399-1404.
- 334 39. Ajamma YU, Onchuru TO, Ouso DO, Omondi D, Masiga DK, Villinger J: Vertical transmission of
 335 naturally occurring Bunyamwera and insect-specific flavivirus infections in mosquitoes from
 336 islands and mainland shores of Lakes Victoria and Baringo in Kenya. 2018, 12(11):e0006949.
- 40. Mease LE, Coldren RL, Musila LA, Prosser T, Ogolla F, Ofula VO, Schoepp RJ, Rossi CA, Adungo N:
 338 Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross 339 sectional study. Virology journal 2011, 8:371.
- Adam A, Seidahmed OM, Weber C, Schnierle B, Schmidt-Chanasit J, Reiche S, Jassoy C: Low
 Seroprevalence Indicates Vulnerability of Eastern and Central Sudan to Infection with
 Chikungunya Virus. Vector borne and zoonotic diseases (Larchmont, NY) 2016, 16(4):290-291.
- António VS, Muianga AF, Wieseler J, Pereira SA, Monteiro VO, Mula F, Chelene I, Chongo IS,
 Oludele JO, Kümmerer BM *et al*: Seroepidemiology of Chikungunya Virus Among Febrile
 Patients in Eight Health Facilities in Central and Northern Mozambique, 2015-2016. Vector
 borne and zoonotic diseases (Larchmont, NY) 2018, 18(6):311-316.
- Jentes ES, Robinson J, Johnson BW, Conde I, Sakouvougui Y, Iverson J, Beecher S, Bah MA,
 Diakite F, Coulibaly M *et al*: Acute arboviral infections in Guinea, West Africa, 2006. The
 American journal of tropical medicine and hygiene 2010, 83(2):388-394.
- Antonio VS, Amade NA, Muianga AF, Ali S, Monteiro V, Mula F, Chelene I, Oludele J:
 Retrospective investigation of antibodies against chikungunya virus (CHIKV) in serum from febrile patients in Mozambique, 2009-2015: Implications for its prevention and control. 2019,
 14(3):e0213941.
- 45. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, Borland E, Gildengorin G,
 355 Pfeil S, Teng CY *et al*: High rates of o'nyong nyong and Chikungunya virus transmission in
 356 coastal Kenya. *PLoS neglected tropical diseases* 2015, 9(2):e0003436.
- 46. Powers AM, Logue CH: Changing patterns of chikungunya virus: re-emergence of a zoonotic
 arbovirus. *The Journal of general virology* 2007, 88(Pt 9):2363-2377.
- 47. Yong LS, Koh KC: A case of mixed infections in a patient presenting with acute febrile illness in
 the tropics. Case reports in infectious diseases 2013, 2013:562175.
- 36148.Makiala-Mandanda S, Ahuka-Mundeke S, Abbate JL, Pukuta-Simbu E, Nsio-Mbeta J, Berthet N,362Leroy EM, Becquart P, Muyembe-Tamfum JJ: Identification of Dengue and Chikungunya Cases

363 364 365 366	49.	Among Suspected Cases of Yellow Fever in the Democratic Republic of the Congo. Vector borne and zoonotic diseases (Larchmont, NY) 2018, 18 (7):364-370. Zeller H, Van Bortel W, Sudre B: Chikungunya: Its History in Africa and Asia and Its Spread to New Regions in 2013-2014 . The Journal of infectious diseases 2016, 214 (suppl 5):S436-s440.
367		
368		
369		
370		
371		